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What’s already known on this topic? 
Low levels of PAPP-A are associated with small for gestational age and pre-
eclampsia. 
 
What does this study add? 
Low maternal serum PAPP-A in the first trimester has an association with adverse 
pregnancy outcome particularly if levels are very low (<1st centile). 
For an individual prediction is poor thus the majority of adverse outcomes will occur 
in the group without an abnormally low PAPP-A.  
Future research is required to develop prediction models and effective interventions. 
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Abstract 
Objectives 
To determine association, and predictive ability, of first trimester maternal serum 
pregnancy associated plasma protein A (PAPP-A) with adverse pregnancy 
outcomes.  
Method 
Searches of Medline, Embase and CINAHL (inception-September 2015) for studies 
including pregnant women with first trimester PAPP-A and assessment of pregnancy 
outcomes.Study characteristics, quality and results extracted. Meta-analysis of odds 
ratios (OR), and likelihood ratios (LR) and 95% confidence intervals (CI). 
Results 
Thirty-two studies including 175,240 pregnancies. PAPP-A <5th centile had a 
moderate association with: Birthweight <10th centile OR 2.08 (95% CI 1.89 – 2.29), 
<5th centile OR 2.83 (95% CI 2.52 – 3.18); pre-eclampsia OR 1.94 (95% CI 1.63 – 
2.30), preterm birth <37 weeks OR 2.09 (95% CI 1.87 – 2.33), and composite 
adverse outcome OR 3.31 (95% CI 1.80 – 5.11). The predictive ability was poor: 
Birthweight <10th centile LR+ve 1.96 (95% CI 1.58 -2.43), LR-ve 0.93 (95% CI 0.89 
– 0.98); Birthweight <5th centile LR+ve 2.65 (95% CI 2.35 -2.99), LR-ve 0.85 (95% 
CI 0.74 – 0.98); PTB <37 weeks LR+ve 1.84 (95% CI 1.41 – 2.39), LR-ve 0.92 (95% 
CI 0.87 – 0.98). 
Conclusions 
First trimester low maternal serum PAPP-A is associated with adverse pregnancy 
outcome but predictive values are poor. Further work should address PAPP-A as a 
continuous variable in combination with other prognostic markers as a prediction 
model.  
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Introduction  
Adverse pregnancy outcomes [stillbirth, preterm birth (PTB), small for gestational 
age (SGA), and hypertensive disorders of pregnancy] have a major psychological 
impact for the family as well as an increased cost for the healthcare system. 
Accurate methods of predicting these outcomes would allow health professionals to 
provide increased surveillance and offer optimum management, which could possibly 
improve the outcome of the pregnancy.  
 
Pregnancy associated plasma protein A (PAPP-A) is a placental glycoprotein 
produced by syncytial trophoblast, which cleaves insulin-like growth factor binding 
protein 4 (IGFBP4) and is a positive regulator of insulin-like growth factors (IGFs)1. 
Biochemical measurement of placental derived factors has been suggested as a 
means to improve fetal and maternal outcome of pregnancy. Previous studies have 
tested the hypothesis that low maternal serum levels of PAPP-A in the first trimester 
can predict adverse pregnancy outcomes associated with poor placental function  2 3, 
4 5 6. The recently published Royal College of Obstetricians and Gynaecologists 
(RCOG) Green top Guidelines assessed all the available evidence prior to their 
publication in 2013 and recommended that in women with a serum PAPP-A <0.415 
multiples of the median (MoM) (5th centile) in the first trimester receive increased 
ultrasound surveillance for growth disorders7. This recommendation was based on a 
previous systematic review by our group in 2008 assessing Down’s syndrome 
markers to predict pre-eclampsia and SGA8. This review included only 16 studies, 
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did not assess all outcomes and did not distinguish between prognosis and 
prediction8. In 2010, first trimester combined screening was routinely introduced in 
the United Kingdom as the recommended screening for Down’s syndrome9. This test 
involves assay of PAPP-A between 10 and 13+6 weeks. Thus since this time, there 
has been a substantial increase in the number of published articles related to this 
placental analyte and therefore a need to systematically review this evidence.  
 
When assessing a biomarker it is important to assess whether there is any 
prognostic association between the “analyte” and outcomes of interest before 
considering the predictive ability of the biomarker to predict the outcome of interest in 
an individual10. It is also important to determine whether PAPP-A has a true 
prognostic ability for adverse pregnancy outcome to determine its use in pregnancy 
surveillance with newer methods of aneuploidy screening such as non-invasive 
prenatal testing with cell free fetal DNA. The aim of this systematic review and meta-
analysis is to improve our understanding of the association between first trimester 
maternal serum PAPP-A levels and pregnancy outcomes and where appropriate to 
evaluate the predictive ability for adverse pregnancy outcomes. 
 
Methods 
A protocol driven systematic review was performed in accordance with published 
guidelines 11 12-15. The reporting of the review meets the criteria specified in the 
PRISMA guidance 15. This is a systematic review consisting of analysis of previously 
reported data and thus ethics approval is not required. 
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Sources 
A literature search was performed in electronic databases from inception till 
September 2015. We searched Embase, MEDLINE, CINAHL (current nursing and 
allied health literature) and Web of Science (grey literature) using combinations of 
relevant medical subject heading (MeSH) terms, keywords and word variants 
(Appendix S1). The reference lists of all included primary and review articles were 
examined to identify articles not captured by electronic searches. A comprehensive 
database collating all citations was constructed using Endnote 7 (Thomson 
Reuters)16.  
 
Study selection and data extraction 
Two independent reviewers scrutinised the data base (RKM and AB partly in 
duplicate). The first stage of study selection was identifying articles based on title or 
abstract with translation of articles with abstracts not in English and removal of 
duplicates. In the second stage, all the citations that were thought to meet the 
predefined selection criterion were obtained. Following examination of full text 
articles by the same reviewers the following inclusion and exclusion decisions were 
made according to adherence to the following criteria: 
 Population: Pregnant women any health care setting, any level of risk. 
 Tests: Serum pregnancy associated plasma protein A measured in the first 
trimester (<14 weeks) 
 Reference standard/outcome: Birth weight, birth weight centile (population 
or customised), maternal (pre-eclampsia, pregnancy induced hypertension, 
gestational diabetes, abruption) and pregnancy outcomes (miscarriage, 
stillbirth, preterm delivery) and a composite adverse pregnancy outcome. 
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 Study design: Observational test accuracy studies (cohorts, case-
control prospective) allowing generation of 2x2 tables of accuracy. Case 
series <10 cases and case-control studies defined by reference standard 
outcome were excluded, these study designs have been shown to be 
associated with bias 17. 
 
No language restrictions were applied to the study. All manuscripts were carefully 
examined to identify overlapping populations. Where this was the case most recent 
and complete manuscripts were selected. Data were extracted on study 
characteristics, quality assessment criteria and results for 2x2 tables (true positive, 
false positive, false negative, true negative) comparing the same threshold of PAPP-
A with an individual outcome were obtained and entered into an Excel spread sheet 
in duplicate by three reviewers (RKM, AB and PD). Discrepancies in data were 
resolved by a fourth reviewer (MDK). 
 
Study Quality assessment 
All studies meeting the pre-defined selection criteria were assessed for 
methodological and reporting quality, defined as confidence that the study design, 
conduct, analysis and reporting minimised any bias in the estimation of the 
association. Quality assessment was based on published guidelines for reporting of 
diagnostic accuracy studies (STARD) and methodological quality (QUADAS-2) 18, 19 
20, 21. The methodological quality items were adopted for the review question and two 
authors independently judged each quality item. In case of discrepancies, consensus 
was reached by discussion.  
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Study quality was assessed in the domains of patient selection, index test, reference 
standard and flow and timing assessing risk of bias and applicability as per 
QUADAS-220. For the population, consecutive or random recruitment of pregnant 
women was considered to be ideal. Prospective recruitment was considered to 
introduce less bias than retrospective recruitment. The description of the population 
was considered ideal if there was sufficient information about the pregnant women 
given to assign a level of obstetric risk, and ideally this risk level was stated by the 
authors in the study’s methods.  
 
The quality of performance and reporting of the index standard (PAPP-A) was 
assessed considering the processes reported for storage of the maternal serum 
sample if needed and the immunoassay analyser used in the lab to quantify the 
levels of serum PAPP A .For the reference standard, any outcome relating to 
maternal, pregnancy or neonatal outcome was considered and information collected 
on method of determination of reference standard, execution and blinding. 
 
Ideal study design were trials or cohort studies, case-control studies were only 
included when cases were not determined by reference standard/outcome as it has 
been shown that this type of study design can affect accuracy 17.  
The assessment of quality is represented by a bar chart.  No attempt was made to 
apply a quality score as this has been shown to have little validity and quality was not 
an aspect for inclusion/exclusion of studies from meta-analysis instead an individual 
assessment was made and this was used to inform investigations into heterogeneity 
in results and sub-group analysis where appropriate 22. 
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Data synthesis and analysis 
From the 2x2 tables the following were calculated with 95% confidence intervals (CI) 
for individual studies: odds ratio (OR), sensitivity, specificity and the likelihood ratios 
(LR). Results were pooled among groups of studies with similar characteristics, the 
same threshold for the index test and same reference standard definition and 
threshold. Studies also reported a composite adverse pregnancy outcome. These 
studies were included in a meta-analysis as long as it could be ensured that 
individuals were only counted once and that the individual outcomes of the 
composite were all of a similar magnitude and direction of effect across the studies 
23. The OR was selected as the summary statistic, as it represents the effect of the 
exposure on the odds in an unbiased fashion and enables the results of both case-
control and cohort studies to be included and provides a measure of the test’s 
prognostic ability 24. 
 
Data were first displayed as forest plots of the OR and 95% CI to allow a visual 
inspection for heterogeneity. Statistical heterogeneity was assessed using the I2 
statistic where I2>50% is significant 25. Random effects meta-analysis was used 
throughout in anticipation of significant clinical and statistical heterogeneity. Where 
there were zero cells within a table a value of 0.5 was added to allow the calculation 
of log ORs and their variances for meta-analysis 26. 
 
To explore for the presence of funnel plot asymmetry (small study effects), and thus 
potential publication bias, the Peters test was performed in each meta-analysis 27. 
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Where there was a moderate statistically significant association between PAPP-A 
and an outcome measure (defined as OR>2 and 95% CI >1) then sensitivity, 
specificity and likelihood ratios were considered, using data from the 2x2 tables. 
Predictive summary measures were synthesised using the bivariate random effects 
prediction model where there were at least four studies in the meta-analysis and 
univariate meta-analysis where this was not possible 28. These measures assess the 
predictive ability of the test i.e. whether the test can accurately discriminate between 
those who do and those who do not have the adverse outcome (sensitivity and 
specificity) and by how much a positive or negative test result modifies the odds of a 
poor outcome (likelihood ratios) 12. Throughout p<0.05 was considered to be 
statistical significance. 
 
All analyses were performed in STATA 10.0 (StataCorp, College Station, TX, USA) 
using the metan, metandi and metabias commands 29-31. Univariate analyses were 
performed in Metadisc 32. 
 
Results 
Figure 1 demonstrates the study selection process with 32 studies being included 
reporting on 175,240 pregnancies 2, 5, 33-62. All studies were performed on secondary 
or tertiary care settings in a low risk or unselected population. All were singleton 
pregnancies except 5 studies where it was not clear that multiples were excluded 
and all excluded fetuses with chromosomal or structural anomalies apart from 6 
studies where again this was not clear. All studies were observational and non-
interventional, 23 were a cohort design, 5 case-control and in 4 the design was 
unclear. Case series were not included as there were sufficient larger studies 
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(smallest n=198).  Recruitment was prospective in 13 studies, retrospective in 16 
and unclear in 3. PAPP-A was performed between 8-14 weeks and various 
thresholds were reported including centile cut-offs and multiples of the median 
(MoM). Outcomes included birth weight <10th centile in 17 studies, <5th centile in 15 
studies  or <3rd centile in 3 studies and >90th centile in 2 studies. Maternal outcomes 
assessed included: 11 studies assessing pre-eclampsia, pregnancy induced 
hypertension in 6 studies, preterm birth <37 weeks in 22 studies and <34 in 2 and 
<32 weeks in 3 studies respectively, gestational diabetes in 1 study, 4 studies 
assessed abruption and 4 studies pregnancy loss <24 weeks. Fetal outcomes 
assessed included 8 studies looking at stillbirth >24 weeks. Six studies reported 
results for a composite adverse pregnancy outcome. Table S1 describes the 
characteristics of the included studies. 
 
Figure 2 displays the bar charts for methodological quality. The assessment of 
patient selection among the included studies showed that two publications were at 
high risk of bias because of being either a case control study (Pawlowski 2013) or 
because exclusions were not clearly described (Spencer 2005) 43, 59. Sensitivity 
analyses with these studies excluded demonstrated no significant difference to 
results. In the other three domains (index test, reference standard and flow and 
timing) all studies were judged overall to have a low risk of bias. When assessing 
applicability one study was deemed to be at high risk as it included patients with 
early onset (second trimester) IUGR (Fox et al 2009)40. The overall high quality of 
the included studies meant that sub-group analysis based on quality was not 
required. 
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Prognostic association 
Table 1 summarises the OR and 95% CI for all analyses. Forest plots for the main 
analyses are shown in Figure 3. Where data was available to look at odds of an 
adverse outcome with PAPPA < 1st centile this demonstrated increasing odds with 
decreasing PAPP-A (Table 1). Three of the analyses demonstrated significant 
heterogeneity (Birthweight <10th, PET and PTB). Inspection of the forest plots and 
table of characteristics could demonstrate no obvious cause for this. 
 
Peter’s test revealed no significant evidence of small study effect across all analyses 
(range p=0.39 – p=0.67) (Funnel plots shown for major meta-analyses in figure S1) 
 
Predictive ability 
Table 1 also summarises the sensitivity, specificity, likelihood ratios (LRs) and 95% 
CI for all analyses. Bivariate meta-analysis was possible for 6 test-outcome 
combinations: PAPP-A <10th centile and birth weight <10th; PAPP-A <5th centile and 
birth weight 10th and <5th centile, pre-eclampsia, preterm birth <37 weeks and 
stillbirth >24 weeks and the hierarchical summary receiver operating characteristic 
curves (HSROC) are shown in Figure S2. Considering those analyses where a 
moderate association had been demonstrated (OR > 2.0 and lower CI > 1.0) the 
following predictive abilities were demonstrated all with a threshold of PAPP-A < 5th 
centile: Birthweight <10th centile LR+ve 1.96 (95% CI 1.58 -2.43), LR-ve 0.93 (95% 
CI 0.89 – 0.98); Birthweight <5th centile LR+ve 2.65 (95% CI 2.35 -2.99), LR-ve 0.85 
(95% CI 0.74 – 0.98); PTB <37 weeks LR+ve 1.84 (95% CI 1.41 – 2.39), LR-ve 0.92 
(95% CI 0.87 – 0.98) and stillbirth >24 weeks LR+ve 1.58 (95% CI 0.67 – 3.71) and 
LR-ve 0.92 (95% CI 0.78 – 1.09). 
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Clinical Interpretation 
The predictive ability of PAPP-A can be converted to a probability of an adverse 
outcome for a low risk nulliparous woman (i.e. no known prior risk) in an unselected 
population with 8000 deliveries a year after a positive test (i.e. posterior test 
probability) using a nomogram (http://araw.mede.uic.edu/cgibin/testcalc.pl) (Table 2). 
Thus following a PAPP-A in the first trimester less than <5th centile a woman would 
have a 1 in 5.6 chance of an SGA baby (birth weight <10th centile) and a 1 in 3.7 of 
any adverse outcome. With lower levels of PAPP-A <1st centile the risks are 
considerably increased with a 1 in 3.6 chance of an SGA baby, 1 in 11 chance of 
pre-eclampsia, 1 in 3.7 chance of preterm birth (<37 weeks), 1 in 10 chance of late 
miscarriage and a 1 in 72 chance of stillbirth. 
 
Conclusion 
Main Findings 
Low maternal serum PAPP-A in the first trimester has an association with adverse 
pregnancy outcome with a moderate association once levels are <5th centile for 
gestation and a stronger association <1st centile. The predictive values are poor, 
thus although women with a low PAPP-A are at increased risk of an adverse 
outcome, the vast majority of these women will have a normal pregnancy outcome 
and the majority of women with an adverse outcome will have a normal PAPP-A. 
 
Strengths and Limitations 
The strength of this review, and consequently the validity of the results for 
assessment of the prognostic and predictive value of PAPP-A, lie in its methodology. 
This included complying with recommended techniques for quality assessment 20 13, 
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performing and interpreting meta-analyses and reporting of our findings 15, 28. Our 
search strategies were comprehensive and robust, evidenced by Peter’s test 
demonstrating no evidence of small study bias. We have considered all aspects of 
test performance and displayed both prognostic and predictive ability of the test as 
well as demonstrating how the test would perform in a sample population. 
 
Limitations within the review relate in the first instance to limitations within the 
included studies. There was significant statistical heterogeneity in some analyses 
which could not be accounted for when examining clinical characteristics nor study 
design and was thus unexplained. Within some analyses there was a lack of data 
and thus for some bivariate meta-analysis could not be performed and for others test 
performance had to be assessed from a single study. We recognise that there are 
other variables that should be considered when assessing risk and that for the 
clinical interpretation we have assumed a background prevalence of the adverse 
outcome. It is not known how risk factors in obstetrics interact and how they modify 
risk in an individual. It is reasonable to assume however that in a woman with 
multiple risk factors e.g. previous SGA baby the risk will be higher than those 
discussed. One limitation in the methodology employed is the need to consider 
PAPP-A as a dichotomous variable i.e. categorisation using a threshold.  This is a 
common technique in clinical research with dichotomization to simplify the analysis. 
This has limitations statistically as it can lead to a loss of power as much of the 
information is lost, classifying very similar factor values as different in opposite sides 
of the cut-off point and the concealment of a potential non-linear relationship 
between the outcome and the factor of interest 63-65. One technique to overcome this 
is individual patient data meta-analysis (IPD), which uses original source data at the 
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participant level thus having many advantages such as being able to derive 
prognostic factor results directly, independent of study reporting and significance, 
and analyse continuous factors more appropriately 66, 67. 
 
Interpretation 
Prognostic factor research is important as it allows us to potentially improve outcome 
for patients by identifying modifiable factors by either intervention e.g. delivery or by 
different management pathways e.g. surveillance. If treatments are available that 
may modify disease then prognostic factors may have a role in predicting differential 
treatment response 68. Even if a prognostic factor is insufficient as a stand-alone test, 
it may still add some independent prognostic value over other prognostic factors, and 
used in a multivariable prognostic model to help provide absolute risk predictions for 
women based on their individual characteristics 68. It is therefore imperative to 
robustly and systematically assess prognostic factors as has been done in this 
review for PAPP-A. 
 
Our results demonstrate evidence of associations between PAPP-A and adverse 
pregnancy outcomes. Future work should thus include IPD meta-analysis as 
previously discussed to allow assessment of PAPP-A as a continuous variable and 
its relationship with other prognostic markers available during the pregnancy; first 
trimester (e.g. crown rump length, nuchal translucency), second trimester (e.g. fetal 
biometry, uterine artery Doppler) and third trimester (e.g. placental biomarkers, 
placental morphology) 69, 70 71, 72 73. Any prognostic model developed would then 
require validation in external data sets 74. At present in UK practice PAPP-A is only 
used as part of combined screening for Down’s syndrome and not as a biomarker for 
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adverse outcome. Before any test (either individual or as a model) is introduced in 
this capacity into practice there must be an assessment of the interventions that may 
be introduced e.g. increased surveillance or pharmacological, to ensure that 
screening in a population is justified and these interventions must be effective in the 
group identified as high risk via the test or model. At present although aspirin has 
been suggested as a possible intervention in certain groups (e.g. those at high risk of 
pre-eclampsia based on previous history) there is no evidence for the effectiveness 
in a group selected by either PAPP-A as a stand-alone test or a model including 
PAPP-A. This allows the clinical effectiveness in reducing the adverse outcome to be 
assessed. However, the results of this systematic review allow appropriate 
counselling of women who have had PAPP-A assessed as part of Down’s syndrome 
screening. 
 
Conclusion  
Low maternal serum PAPP-A in the first trimester has an association with adverse 
pregnancy outcome particularly if levels are very low (<1st centile). It must be 
recognised that for the individual, predictive values are poor and the majority of 
adverse outcomes will occur in the group without an abnormally low PAPP-A. There 
are also no proven interventions in this group. Therefore, future research is required 
to develop robust and accurate prediction models and effective interventions that can 
allow modern day obstetrics to practice truly stratified medicine 75. 
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Table 1: Meta-analysis summary of studies for systematic review of association and prediction of first trimester maternal serum pregnancy associated plasma protein A 
(PAPPA) and adverse pregnancy outcomes.  
Pregnancy outcome/                          
PAPPA threshold 
Numbe
r of 
include
d 
studies 
Numbe
r 
include
d in 
analyse
s 
Odd
s 
ratio 
95% 
Confidenc
e interval 
Sensitivit
y 
95% 
Confidenc
e interval 
Specificit
y 
95% 
Confidenc
e Interval 
Positive 
Likelihoo
d ratio 
95% 
Confidenc
e Interval 
Negative 
Likelihoo
d ratio 
95% 
Confidenc
e Interval 
Birth weight <10th 
centile 17 65078 
          <10th centile 
*
 7 44316 1.88 1.72-2.05 0.16 0.14 -0.19 0.90 0.89 - 0.90 1.64 1.45 - 1.88 0.92 0.90 - 0.95 
<5th centile 
*
 12 59927 2.08 1.89-2.29 0.13 0.08 -0.2 0.94 0.90 - 0.96 1.96 1.58 -2.43 0.93 0.89 - 0.98 
< 1st centile 2 39671 3.40 2.70 - 4.26 0.03 0.02 -0.04 0.99 0.99 - 0.99 3.49 2.51 - 4.89 0.98 0.98 - 0.99 
<0.5MoM 3 4916 1.60 1.23 - 2.07 0.19 0.15 - 0.23 0.88 0.87 - 0.89 1.96 1.02 - 3.76 0.88 0.77 - 1.02 
<0.3 MoM 2 3912 1.55 0.97 - 2.48 0.06 0.04 -0.09 0.96 0.96 - 0.97 1.93 0.72 - 5.20 0.97 0.90 - 1.04 
Birth weight <5th 
centile 15 134825                     
<10th centile 4 39714 2.29 2.01 - 2.60 0.20 0.18 - 0.22 0.90 0.90 - 0.90 2.17 1.64 - 2.87 0.90 0.85 - 0.94 
<5th centile
*
 11 72245 2.83 2.52-3.18 0.22 0.10 - 0.41 0.92 0.84 - 0.96 2.65 2.35 - 2.99 0.85 0.74 - 0.98 
 <1st centile 2 45750 4.66 3.61 - 6.01 0.04 0.03 - 0.05 0.99 0.99 - 0.99 4.52 3.53 - 5.78 0.97 0.96 - 0.98 
<0.5MoM 2 4550 2.12 1.53 - 2.95 0.25 0.19 - 0.32 0.86 0.85 - 0.87 1.99 1.23 - 3.22 0.84 0.68 -1.03 
<0.3MoM 2 22464 3.13 2.30 - 4.26 0.12 0.09 -0.16 0.96 0.95 - 0.96 2.89 2.21 - 3.79 0.92 0.88 - 0.97 
Birth weight <3rd 
centile 3 8935                     
<5th centile 2 8108 2.76 1.78 - 4.28 0.12 0.08 -0.18 0.95 0.95 - 0.96 2.58 1.75 - 3.79 0.93 0.88 -0.98 
<0.5 MoM 2 3692 1.89 1.19 - 3.01 0.23 0.15 - 0.32 0.87 0.85 - 0.88 1.69 1.18 - 2.42 0.89 0.80 -0.99 
 <0.3 MoM 2 3692 2.68 1.37 - 5.27 0.10 0.05 - 0.17 0.96 0.96 - 0.97 2.53 1.37 - 4.67 0.94 0.88 -1.00 
Birth weight > 90th 
centile 2 35545                     
 <10th centile 2 35545 0.50 0.35 - 0.71 0.05 0.04 -0.08 0.90 0.90 -0.90 0.53 0.38 - 0.74 1.05 1.03 - 1.08 
< 5th centile 2 35545 0.42 0.24 - 0.72 0.02 0.01 - 0.04 0.95 0.95 - 0.95 0.44 0.25 -0.75 1.03 1.02 - 1.04 
Pre-eclampsia 11 71195                     
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< 10th centile 3 38956 1.42 1.18 - 1.72 0.14 0.12 - 0.16 0.90 0.89 - 0.90 1.55 1.06 - 2.27 0.94 0.88 - 1.01 
 < 5th centile
*
 8 132076 1.94 1.63-2.30 0.16 0.09 - 0.28 0.92 0.85 - 0.96 1.95 1.48 - 2.56 0.91 0.86 - 0.97 
< 1st centile 2 45750 2.27 1.43 - 3.62 0.02 0.01 - 0.04 0.99 0.99 - 0.99 4.91 
0.60 - 
40.19 0.95 0.83 - 1.08 
Pregnancy induced 
hypertension 6 8562                     
< 10th centile 2 5561 2.83 1.71 - 4.68 0.24 0.15 - 0.34 0.90 0.19 - 0.91 2.47 1.68 - 3.63 0.91 0.73 - 1.13 
< 0.5 MoM 2 2124 5.07 2.78 - 9.27 0.47 0.31 - 0.62 0.86 0.84 - 0.87 2.80 
0.25 - 
31.57 0.43 0.03 -7.48 
< 0.4 MoM 2 877 2.68 1.40 - 5.10 0.18 0.1 - 0.28 0.92 0.90 - 0.94 2.31 1.37 - 3.90 0.91 0.83 - 1.00 
Pre-term birth <37 
weeks 22 107324                     
< 10th centile 3 38956 1.52 1.35 - 1.71 0.15 0.13 - 0.16 0.90 0.89 - 0.90 1.45 1.31 - 1.60 0.95 0.93 - 0.97 
 < 5th centile
*
 7 66133 2.09 1.87-2.33 0.16 0.09 - 0.29 0.91 0.83 - 0.96 1.84 1.41 - 2.39 0.92 0.87 - 0.98 
< 1st centile 2 45750 3.63 2.89 - 4.55 0.03 0.03 - 0.04 0.99 0.99 - 0.99 4.28 1.50-12.25 0.97 0.94 - 1.00 
 < 0.6 MoM 2 4938 1.69 1.36 - 2.11 0.32 0.27 - 0.37 0.78 0.77 - 0.80 1.48 1.21 - 1.80 0.87 0.81 - 0.94 
< 0.5 MoM 3 2946 3.02 2.16 - 4.22 0.30 0.23 - 0.37 0.87 0.86 - 0.88 2.31 0.62 - 8.55 0.75 0.52 - 1.09 
< 0.4 MoM 3 12231 1.94 1.50 - 2.49 0.10 0.08 - 0.12 0.95 0.95 - 0.95 1.85 1.48 - 2.32 0.95 0.90 - 1.00 
< 0.3 MoM 3 13060 2.11 1.50 - 2.95 0.05 0.04 - 0.07 0.98 0.98 - 0.98 1.86 0.95 - 3.64 0.98 0.96 - 1.00 
Pre-term birth <34 
weeks 2 13012                     
< 5th centile 2 13012 2.51 1.48 - 4.25 0.17 0.13 - 0.21 0.90 0.90 - 0.90 1.69 1.31 -2.16 0.93 0.88 - 0.97 
< 1st centile 1 7769 2.37 0.57 - 9.81 0.02 0.02 - 0.07 0.99 0.99 - 0.99 2.34 0.58 - 9.41 0.99 0.96 - 1.02 
Pre-term birth <32 
weeks 3 42690                     
<10th centile 2 35623 1.82 1.35 - 2.45 0.17 0.13 - 0.21 0.90 0.90 - 0.90 1.69 1.31 - 2.16 0.93 0.88 - 0.97 
< 5th centile 3 42690 2.25 1.60 - 3.17 0.12 0.09 - 0.16 0.95 0.94 - 0.95 1.99 1.49 - 2.65 0.94 0.91 - 0.98 
< 1st centile 1 33395 3.26 1.60 - 6.65 0.03 0.01 - 0.06 0.99 0.99 - 0.99 3.19 1.6 - 6.36 0.98 0.96 - 1.0 
Stillbirth >24 weeks 8 47916                     
< 10th centile 2 33593 1.84 1.08 - 3.12 0.17 0.10 - 0.26 0.90 0.90 - 0.90 4.74 
0.43 - 
52.33 0.85 0.43 - 1.70 
 < 5th centile
*
  5 44575 2.40 1.45-3.99 0.18 0.08 - 0.36 0.88 0.80 - 0.94 1.58 0.67 - 3.71 0.92 0.78 - 1.09 
<1st centile 1 33395 3.04 0.96 - 9.63 0.03 0.01-0.09 0.99 0.99 - 0.99 2.97 0.97 - 9.09 0.98 0.94 - 1.01 
 < 0.5 MoM 2 2119 5.74 
0.81 - 
40.70 0.50 0.01 - 0.99 0.85 0.84 - 0.87 4.10 
1.22 - 
13.70 0.71 0.22 - 2.26 
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Pregnancy loss ≤24 
weeks 4 49986                     
 < 10th centile 2 38692 2.12 1.62 - 2.77 0.19 0.15 - 0.24 0.90 0.90 -0.90 1.91 1.53 - 3.37 0.90 0.85 - 0.95 
 < 5th centile 2 38692 2.50 1.81 - 3.47 0.12 0.09 - 0.16 0.95 0.95 - 0.95 2.25 1.47 - 3.46 0.94 0.99 - 1.00 
<1st centile 1 33395 5.48 3.28 - 9.17 0.05 0.03 - 0.09 0.99 0.99 - 0.99 5.24 3.21 - 8.53 0.96 0.93 - 0.98 
Gestational diabetes 1 5243                     
< 5th centile 1 5243 4.17 2.00 - 8.69 0.18 0.09- 0.32 0.95 0.94 - 0.96 3.59 1.97 - 6.55 0.86 0.75 - 0.98 
Abruption 4 6368                     
< 5th centile 2 2565 2.73 0.81 - 9.23 0.31 0.09 - 0.61 0.82 0.8 - 0.83 2.74 
0.62 - 
12.17 0.80 0.56 - 1.15 
Composite adverse 
outcome 6 15930                     
< 10th centile 2 1076 4.50 2.55 - 7.95 0.29 0.18 - 0.41 0.92 0.9 - 0.93 3.48 2.28 - 5.32 0.78 0.67 - 0.91 
< 5th centile 3 13431 3.31 2.76 - 3.97 0.12 0.1 - 0.14 0.96 0.96 - 0.96 3.05 2.59 - 3.59 0.92 0.9 - 0.93 
< 0.4 MoM 2 877 3.03 1.80 - 5.11 0.17 0.12 - 0.24 0.93 0.91 - 0.95 2.60 1.69 - 4.0 0.89 0.77 - 1.02 
PAPPA - pregnancy associated plasma protein 
A 
          MoM multiples of median 
           * bivariate meta-analysis 
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Table 2: Clinical use of first trimester pregnancy associated plasma protein A.  
Pregnancy outcome/                          
PAPPA threshold 
Positive 
Likelihood 
ratio 
95% 
Confidence 
Interval 
Negative 
Likelihood 
ratio 
95% 
Confidence 
Interval 
Prevalence
$
 
(%) 
Posterior probability 
after positive test % 
(number with positive 
test who have 
outcome) 
Posterior probability after 
negative test % (number 
with negative test without 
outcome) 
PAPPA <5th centile 
       Birth weight<10th centile 
*
 1.96 1.58 -2.43 0.93 0.89 - 0.98 10 18% (1 in 5.6) 9% (1 in 1.1) 
Birth weight <5th centile
*
 2.65 2.35 - 2.99 0.85 0.74 - 0.98 5 12% (1 in 8.2) 4% (1 in 1.0) 
Pre-eclampsia 1.95 1.48 - 2.56 0.91 0.86 - 0.97 2 4% (1 in 26) 2% (1 in 1.0) 
Preterm birth <37 weeks 1.84 1.41 - 2.39 0.92 0.87 - 0.98 8 12% (1 in 8.1) 7% (1 in 1.1) 
Preterm birth <34 weeks 1.69 1.31 -2.16 0.93 0.88 - 0.97 2.4 4% (1 in 25) 2% (1 in 1.0) 
Preterm birth <32 weeks 1.99 1.49 - 2.65 0.94 0.91 - 0.98 1.4 3% (1 in 36) 1% (1 in 1.0) 
Pregnancy loss < 24 weeks 2.25 1.47 - 3.46 0.94 0.99 - 1.00 2 4% (1 in 23) 2% (1 in 1.0) 
 Stillbirth>24 weeks
*
  1.58 0.67 - 3.71 0.92 0.78 - 1.09 0.47 1% (1 in 135) 0% (1 in 1.0) 
Composite adverse 
outcome 3.05 2.59 - 3.59 0.92 0.9 - 0.93 11 27% (1 in 3.7) 10% (1 in 1.1) 
PAPPA <1st centile         
   Birth weight <10th centile 3.49 2.51 - 4.89 0.98 0.98 - 0.99 10 28% (1 in 3.6) 10% (1 in 1.1) 
 Birth weight <5th centile 4.52 3.53 - 5.78 0.97 0.96 - 0.98 5 19% (1 in 5.2) 5% (1 in 1.1) 
Pre-eclampsia 4.91 
0.60 - 
40.19 0.95 0.83 - 1.08 2 9% (1 in 11) 2% (1 in 1.0) 
Preterm birth <37 weeks 4.28 1.50-12.25 0.97 0.94 - 1.00 8 27% (1 in 3.7) 8% (1 in 1.1) 
Preterm birth <34 weeks 2.34 0.58 - 9.41 0.99 0.96 - 1.02 2.4 5% ( 1 in 18) 2% (1 in 1.0) 
Preterm birth <32 weeks 3.19 1.6 - 6.36 0.98 0.96 - 1.0 1.4 4% (1 in 23) 1% (1 in 1.0) 
Pregnancy loss < 24 weeks 5.24 3.21 - 8.53 0.96 0.93 - 0.98 2 10% (1 in 10) 2% (1 in 1.0) 
Stillbirth > 24 weeks 2.97 0.97 - 9.09 0.98 0.94 - 1.01 0.47 1% (1 in 72) 0% (1 in 1.0) 
PAPPA - pregnancy associated plasma protein A 
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MoM multiples of median 
       * bivariate meta-analysis 
       
$ Prevalence data obtained from ONS 2014 
(http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/bulletins/birthsummarytablesenglandandwales/2015-07-
15) 
Pre-eclampsia prevalence from NICE guidelines "Hypertension in Pregnancy: the management of hypertensive disorders during pregnancy" . National 
Collaborating Centre for Women's and Children's Health. 2010 
Late miscarriage prevalence from Wyatt PR,OwolabiT, Meier C, Huang T.Age-specific risk of fetal loss observed in a second trimester serum screening 
population.Am J Obstet Gynecol 2005;192:240–6 
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Figure 1 Process from initial search to final inclusion for association and 
prediction of first trimester serum pregnancy associated plasma protein A 
(PAPPA) with adverse pregnancy outcomes (inception to September 2015).  
Primary articles retrieved for detailed evaluation  
- from electronic searches      N= 271 
- from reference lists     N= 5 
         
Articles excluded     n= 244    
- not prediction/ not test accuracy   n= 66   
- reviews/ letters/ comments/ editorials   n= 37   
- Not PAPPA     n= 7   
- not within first trimester    n= 12   
- insufficient data to construct 2x2 table   n= 120   
- other       n= 2   
   
Primary articles included in systematic review   n= 32  
  
Potentially relevant citations identified from electronic searches to capture primary articles on all 
studies assessing first trimester serum PAPPA and pregnancy outcome 
N= 1715 
Potentially relevant citations on title and abstract review after removing duplicates  
     N= 310 
References excluded after screening titles and/ or abstracts  
      N= 34 
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Figure 2: Bar chart to demonstrate methodological quality of included studies in systematic review of association of pregnancy associated 
plasma protein A with adverse pregnancy outcomes assessed by QUADAS-219 
 This article is protected by copyright. All rights reserved. 
Figure 3: Forest plots of odds ratios in systematic review of pregnancy associated plasma protein A with adverse 
pregnancy outcomes. 
 
 
 
Figure 3A: Forest plot for association (odds ratio) of pregnancy associated plasma protein A (PAPPA) 
<10th centile with birth weight <10th centile 
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Figure 3B: Forest plot for association (odds ratio) of pregnancy associated plasma protein A (PAPPA) 
<5th centile with birth weight <10th centile 
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Figure 3C: Forest plot for association (odds ratio) of pregnancy associated plasma protein A (PAPPA) 
<5th centile with birth weight <5th centile 
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Figure 3D: Forest plot for association (odds ratio) of pregnancy associated plasma protein A (PAPPA) 
<5th centile with pre-eclampsia 
  
Overall  (I-squared = 53.2%, p = 0.037) 
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Figure 3E: Forest plot for association (odds ratio) of pregnancy associated plasma protein A (PAPPA) 
<5th centile with pre-term birth <37 weeks 
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Figure 3F: Forest plot for association (odds ratio) of pregnancy associated plasma protein A (PAPPA) 
<5th centile with stillbirth >24 weeks 
Overall  (I-squared = 53.6%, p = 0.071) 
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